Uploaded August 2026 | Updated November 2026, 3 days ago
"One-Plant Policy Panel" panel discussion at CannMed 2026, covering one-plant policy, hemp cannabis regulation, and federal cannabis policy.
As cannabis moves toward federal recognition, legalization is the entry point, not the destination. This opening panel frames the One-Plant Policy as a public-health and regulatory principle: when cannabis and hemp are intended for human consumption, they should be governed by the same safety expectations, analytical standards, and evidence thresholds, regardless of THC concentration.
Using a federal lifecycle lens of legalization, standardization, and data-validated outcomes, panelists examine how coordinated alignment across FDA, USDA, and DEA can replace fragmented state rules with harmonized oversight that protects patients and consumers, enables consistent products, and scales commerce responsibly.
Key topics include FDA regulatory lanes bridging medical cannabis, hemp-derived cannabinoids, supplements, and pharmaceuticals; protections for minors and medical patients within adult-use systems; and how U.S. legalization can catalyze Codex, USP, and ISO alignment for global markets.
Panelists:
Mike Hennesy (Moderator), Principal, Hennesy Strategy
Jordan Wellington, Managing Partner, Strategies 64
Dustin Sulak, DO, Co-Founder & Medical Director, Healer.com
Steph Sherer, Board President and Executive Director, Americans for Safe Access
This presentation was given at the CannMed 2026 Innovation & Collaboration Summit, held June 15-18 at the Hyatt Regency Lake Tahoe Resort. Visit cannmedevents.com to learn more.
"One-Plant Policy Panel" panel discussion at CannMed 2026, covering one-plant policy, hemp cannabis regulation, and federal cannabis policy.
As cannabis moves toward federal recognition, legalization is the entry point, not the destination. This opening panel frames the One-Plant Policy as a public-health and regulatory principle: when cannabis and hemp are intended for human consumption, they should be governed by the same safety expectations, analytical standards, and evidence thresholds, regardless of THC concentration.
Using a federal lifecycle lens of legalization, standardization, and data-validated outcomes, panelists examine how coordinated alignment across FDA, USDA, and DEA can replace fragmented state rules with harmonized oversight that protects patients and consumers, enables consistent products, and scales commerce responsibly.
Key topics include FDA regulatory lanes bridging medical cannabis, hemp-derived cannabinoids, supplements, and pharmaceuticals; protections for minors and medical patients within adult-use systems; and how U.S. legalization can catalyze Codex, USP, and ISO alignment for global markets.
Panelists:
Mike Hennesy (Moderator), Principal, Hennesy Strategy
Jordan Wellington, Managing Partner, Strategies 64
Dustin Sulak, DO, Co-Founder & Medical Director, Healer.com
Steph Sherer, Board President and Executive Director, Americans for Safe Access
This presentation was given at the CannMed 2026 Innovation & Collaboration Summit, held June 15-18 at the Hyatt Regency Lake Tahoe Resort. Visit cannmedevents.com to learn more.










![Recruitment Challenges for Cannabis Clinical Trials - Emily Lindley, PhD & Rachael Rzasa Lynn, MD
Dr. Emily Lindley is Assistant Professor of Orthopedics and Director of the Colorado Cannabis Research Consortium. Her team’s research aims to identify non-opioid alternatives for the treatment of chronic musculoskeletal pain. One such alternative that has gained increased recognition in recent years is medical cannabis, and her lab is currently studying the health effects of cannabis and cannabinoids for chronic musculoskeletal pain.
Dr. Rachael Rzasa Lynn is a board certified in pain medicine physician and is an Associate Professor in the Department of Anesthesiology at the University of Colorado, where she is the Associate Program Director for the Pain Medicine Fellowship. Her research includes investigations in opioid pharmacology and the use of cannabis for chronic pain.
Rachel and Emily co-authored a poster presented at the most recent ICRS conference titled, Recruitment Challenges in Clinical Studies of Cannabis
During our conversation, we discussed:
* How recruitment for cannabis clinical trials differs from traditional clinical trials
* Why prior experience with cannabis is considered a negative for patient recruitment
* How legal concerns and stigma can deter cannabis-naive patients from enrolling
* Why the participant drop out rate is higher in cannabis trials
* How rescheduling may affect patient recruitment for future trials
Thanks to This Episodes Sponsor: The Society of Cannabis Clinicians
The Society of Cannabis Clinicians’ Med Cann conference offers a rare opportunity for clinicians to dive deep into the clinical realities and therapeutic potential of medical cannabis and psychedelics. Designed with healthcare providers in mind, their sessions focus on case-based learning, emerging protocols, and real-world challenges—offering practical insights that can be immediately applied in your practice.
Learn more at cannabisclinicians.org and use code CP15 to receive 15% Off Your Registration
Additional Resources
* Recruitment Challenges in Clinical Studies of Cannabis [Poster] - https://cannmedevents.com/wp-content/uploads/2025/08/P2-21-Recruitment-Challenges-Poster-ICRS-2025.pdf
* Lindley Lab at the University of Colorado - https://medschool.cuanschutz.edu/orthopedics/research/labs/lindley-lab/our-research Recruitment Challenges for Cannabis Clinical Trials - Emily Lindley, PhD & Rachael Rzasa Lynn, MD](https://i.ytimg.com/vi/TV5x6dQ6AMs/mqdefault.jpg)